title: Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism.
abstract: OBJECTIVE
  Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol synthesis, lowers plasma cholesterol and triglyceride (TG) levels dose dependently. The aim of this study was to investigate the molecular mechanism(s) of this decrease in plasma TG levels in atorvastatin-treated subjects.
  
  
  METHODS
  Lipoprotein separation and plasma analysis of lipids, glucose and insulin were performed in subjects randomly assigned to placebo (n = 9) or atorvastatin (80 mg per day) (n = 10) for 4 weeks. Liver TG mass was determined in pooled samples. Hepatic expression of several genes involved in carbohydrate and TG metabolism was determined.
  
  
  RESULTS
  Atorvastatin lowered plasma levels of very low-density lipoprotein (VLDL) TG (∼50%, P < 0.05) and liver TG mass compared to placebo. Except for cholesterol changes, there were no other significant differences in plasma lipids, glucose or insulin. However, atorvastatin reduced mRNA expression of sterol regulatory element-binding protein 1c (SREBP1c) (>30%, P < 0.05), glucokinase (∼50%, P < 0.05) and angiopoietin-like protein 3 (ANGPTL3) (∼25%, P < 0.01), and induced mRNA expression of acetyl-coenzyme A carboxylase 1 (∼45%, P < 0.05) and glucose-6-phosphatase (∼90%, P < 0.05) compared to placebo.
  
  
  CONCLUSIONS
  Following treatment with atorvastatin, reduced ANGPTL3 mRNA expression may contribute to the reduced plasma levels of VLDL TG. The reduced liver TG mass induced by a high dosage of atorvastatin may be important for the treatment of patients with fatty liver.
authors.affiliation: Department of Laboratory Medicine, Division of Clinical Chemistry, Karolinska Institutet at Danderyd Hospital, Danderyd, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Pramfalk
authors.forename: P
authors.initials: P
authors.lastname: Parini
authors.forename: U
authors.initials: U
authors.lastname: Gustafsson
authors.forename: S
authors.initials: S
authors.lastname: Sahlin
authors.forename: M
authors.initials: M
authors.lastname: Eriksson
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D002241:Carbohydrates / Q000097:blood*; D004334:Drug Administration Schedule; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D014280:Triglycerides / Q000097:blood*
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D002241:Carbohydrates; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007328:Insulin; D008055:Lipids; D011758:Pyrroles; D014280:Triglycerides; D000069059:Atorvastatin